CINXE.COM

<!DOCTYPE html><html lang="en"><head><link rel="stylesheet" data-href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap" data-optimized-fonts="true"/><title>Psychedelic medicines and the treatment of neurological conditions</title><link rel="icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png"/><link rel="shortcut icon" type="image/x-icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="apple-touch-icon" sizes="180x180" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="canonical" href="/domains/magazine.pharmafile.com/articles/psychedelic-medicines-and-the-treatment-of-neurological-conditio"/><meta name="application-name" content="Psychedelic medicines and the treatment of neurological conditions"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="default"/><meta name="apple-mobile-web-app-title" content="Psychedelic medicines and the treatment of neurological conditions"/><meta name="format-detection" content="telephone=no"/><meta name="mobile-web-app-capable" content="yes"/><meta name="msapplication-TileColor" content="#1976D2"/><meta name="msapplication-tap-highlight" content="no"/><link rel="manifest" href="/manifest.json"/><meta name="twitter:url" content="https://magazine.pharmafile.com"/><meta name="theme-color" content="#1976D2"/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta charSet="utf-8"/><meta itemProp="name" content="Psychedelic medicines and the treatment of neurological conditions"/><meta name="keywords" content="psychedelic medicines and the treatment of"/><meta itemProp="description" content="Rob conley from beckley psytech tells pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and ho"/><meta name="description" content="Rob conley from beckley psytech tells pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and ho"/><meta itemProp="image" content="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg"/><meta property="og:description" content="Rob conley from beckley psytech tells pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and ho"/><meta property="og:title" content="Psychedelic medicines and the treatment of neurological conditions"/><meta property="og:site_name" content="Psychedelic medicines and the treatment of neurological conditions"/><meta property="og:image" content="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Psychedelic medicines and the treatment of neurological conditions"/><meta name="twitter:description" content="Rob conley from beckley psytech tells pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and ho"/><meta name="twitter:image" content="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg"/><meta name="author" content="Pharmafile"/><meta property="article:author" content="Pharmafile"/><meta property="article:published_time" content="2024-05-21T00:00:00.000Z"/><meta name="twitter:site" content="@pharmafocus"/><meta name="twitter:creator" content="@pharmafocus"/><style>html{--heading-font: "Roboto Slab";--body-font: "Open Sans";--ui-font: "Roboto";--top-menu-title-font: "Roboto Slab";--top-menu-subtitle-font: "Roboto";--top-menu-items-font: "Roboto";--footer-menu-title-font: "Roboto Slab";--footer-menu-items-font: "Roboto";--background-color: #FFFFFF;--background-color-dark: #808080;--primary-color: #1976D2;--primary-color-dark: #0C3B69;--secondary-color: #795FF4;--secondary-color-dark: #250B9F;--accent-color: #D76FD6;--accent-color-dark: #80237F;--info-color: #41638C;--info-color-dark: #213246;--warning-color: #EF9338;--warning-color-dark: #89490B;--success-color: #20AD27;--success-color-dark: #105714;--danger-color: #DF4241;--danger-color-dark: #7B1515;--top-menu-background-color: #FFFFFF;--top-menu-background-color-dark: #808080;--footer-menu-background-color: #000000;--footer-menu-background-color-dark: #000000;--top-menu-heading-title-color: #000000;--top-menu-heading-title-color-dark: #000000;--top-menu-item-text-color: #000000;--top-menu-item-text-color-dark: #000000;--top-menu-item-icon-color: #000000;--top-menu-item-icon-color-dark: #000000;--navbar-height: 64px; }</style><link rel="stylesheet" data-href="https://use.typekit.net/nat8xfl.css" data-optimized-fonts="true"/><script type="text/javascript" src="https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1&always=1&showNoConsent=1"></script><meta name="google-site-verification" content="1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0"/><style> #billboard-banner { text-align:center;} #billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;} </style><meta name="next-head-count" content="43"/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com"/><link rel="preload" href="/_next/static/css/229efe2956472d85.css" as="style"/><link rel="stylesheet" href="/_next/static/css/229efe2956472d85.css" data-n-g=""/><link rel="preload" href="/_next/static/css/7c74bf24f71f6c9d.css" as="style"/><link rel="stylesheet" href="/_next/static/css/7c74bf24f71f6c9d.css" data-n-p=""/><link rel="preload" href="/_next/static/css/eaa0062c2481f7ca.css" as="style"/><link rel="stylesheet" href="/_next/static/css/eaa0062c2481f7ca.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" data-nscript="beforeInteractive"></script><script src="/_next/static/chunks/webpack-b653c683a51d8b57.js" defer=""></script><script src="/_next/static/chunks/framework-73b8966a3c579ab0.js" defer=""></script><script src="/_next/static/chunks/main-34cb81d5753e1fc4.js" defer=""></script><script src="/_next/static/chunks/pages/_app-9cc101b503fd5646.js" defer=""></script><script src="/_next/static/chunks/ad273671-3092333ffa02af02.js" defer=""></script><script src="/_next/static/chunks/876-c944523f292a2885.js" defer=""></script><script src="/_next/static/chunks/223-fe6833f316a5a95f.js" defer=""></script><script src="/_next/static/chunks/174-d95909d2aa5e8ec8.js" defer=""></script><script src="/_next/static/chunks/302-d0f1826200f9f2a4.js" defer=""></script><script src="/_next/static/chunks/pages/domains/%5Bdomain%5D/articles/%5Bslug%5D-12d0888066c7f18b.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_buildManifest.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="5.3.9"></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap"/><link rel="stylesheet" href="https://use.typekit.net/nat8xfl.css"/></head><body><div id="__next"><div class="Layout_container__gktH6"><div class="Layout_navbar-container__gCfDZ" style="height:64px"><nav class="_wrapper_jbnbd_1"><div class="_container_jbnbd_15"><div class="_navbar-prefix_jbnbd_108"><div class="Layout_prefix__7W2Vq"><button><div class="_nav-arrow-left_1lm7t_183 _icon_1lm7t_1 icon"></div></button></div></div><a class="_navbar-brand_jbnbd_29" aria-label="Pharmafile" href="/"><div class="_navbar-image_jbnbd_40"><img alt="Logo" loading="lazy" decoding="async" data-nimg="fill" class="_image_jbnbd_43" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 54w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 70w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 82w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 96w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 110w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 128w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 138w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 192w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 252w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 260w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 298w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 378w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 384w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 520w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 640w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 756w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 828w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1080w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1920w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 2048w" src="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png"/></div><div class="_navbar-title_jbnbd_58 _navbar-title-hide_jbnbd_101"><span>Therapeutic areas in focus</span></div></a><div id="navbar-children-container" class="_navbar-children_jbnbd_116"><div class="_menu_1jhrl_1"><div class="_menu-wrapper_1jhrl_22"><div class="_menu-items_1jhrl_38"><a class="_menu-item_1jhrl_38" href="/"><div class="_menu-home_1lm7t_255 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Home</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38 _active_1jhrl_70" href="/articles"><div class="_menu-articles_1lm7t_259 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Articles</div><div class="_indicator_1jhrl_63 _active_1jhrl_70"></div></a><a class="_menu-item_1jhrl_38" href="/collections"><div class="_menu-issues_1lm7t_263 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Issues</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38" href="/account/login"><div class="_menu-account_1lm7t_411 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Log in</div><div class="_indicator_1jhrl_63"></div></a></div></div></div></div><div id="navbar-suffix" class="_navbar-suffix_jbnbd_108"><div class="Layout_menu-actions__vsDbI"><div class="Layout_install-button__FBfSr"><div class="Tooltip_tooltip__98Sw9"></div><button class="_button_19h3g_1 _text_19h3g_12 _medium_19h3g_38 _secondary_19h3g_22" type="button" style="color:var(--top-menu-item-icon-color, var(--background-color))" role="button" aria-label="Search" aria-labelledby="labeldiv" title="Search"><div class="_action-search_1lm7t_15 _icon-button_19h3g_19 _icon_1lm7t_1 icon" style="background-color:var(--top-menu-item-icon-color, var(--background-color))"></div></button></div></div></div></div></nav></div><div class="Layout_main__evUHx"><div class="Layout_spacer__qTBD3" style="height:64px"></div><div class=""><div class=""></div><div class=""><div id="print-article" class="_slug__article__BPEHu"><div class="Article-module_article__kO4b9"><div id="outer" data-widget="page-widget" style="background-color:#FFFFFF;padding:16px 0px 24px 0px;color:#000000;text-align:left;font-family:"Open Sans"" class="Widget-module_outer__PBh8P Page-module_outer__g0XXH"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>PSYCHOACTIVES</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h2><span style="font-family:"Roboto Slab"" class="__bold">Psychedelic medicines and the treatment of neurological conditions</span></h2></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:rgba(240,9,121,1);padding:8px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(0,0,0)"><span style="color:rgb(255, 254, 254)">Rob Conley from Beckley Psytech tells </span><span class="__italic" style="color:rgb(255, 254, 254)">Pharmafile </span><span style="color:rgb(255, 254, 254)">about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future</span></span></p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:8px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">What is the current treatment landscape for psychiatric and neurological conditions?</span><span class="__italic"> </span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">Rob Conley (RC): </span>Psychiatric conditions like depression and anxiety are primarily managed today through a combination of lifestyle changes, talking therapies and medications, with selective serotonin reuptake inhibitors (SSRIs) being the most common drugs prescribed by doctors or physicians for depression. Neurological conditions often have a different set of interventions available, combining a mix of physical therapy, medications and cognitive rehabilitation exercises. For many people living with neuropsychiatric conditions, the currently available treatments work for them but for others, there can be limited efficacy and challenges that limit treatment adherence, including undesirable side effects and a slow onset of action. Despite many years of work and experience in this field, there remains a strong need for new approaches in order to improve patient outcomes and reduce the burden these conditions have on individuals, healthcare systems and society more generally.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">What are the issues with current treatments for these conditions?</span><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)"> </span></span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">RC: </span>There are several challenges with the current treatment paradigm for neuropsychiatric conditions, and it may be helpful to look at depression, which typifies a lot of the hurdles we see within the space. For many patients, overcoming the stigma of accessing treatment or therapy <span>is a big challenge, but once they get over that, there are still several difficulties they may encounter with the drug treatments themselves. Antidepressants and SSRIs may carry unwanted side effects like weight gain, sedation and sexual dysfunction that can lead to poor adherence and treatment discontinuation, while the slow onset of action of some medications can delay symptomatic relief and prolong a patients’ suffering. Antidepressants also have limited efficacy, with many people experiencing treatment resistance. Indeed, 33% of patients diagnosed with depression are resistant to available treatments and 60% of patients with depression discontinue or switch SSRI within 12 weeks.</span><span class="__superscript">1,2 </span><span>For those living with treatment resistant depression (TRD), which is characterised when an individual with depression does not respond to two or more courses of antidepressants, treatment opportunities are sadly lacking and there is an urgent need for more effective treatments. Similar challenges can be seen across the treatment landscape for other psychiatric and neurological conditions.</span></p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">How can psychedelic medicines improve treatment of these illnesses?</span><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)"> </span></span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">RC: </span>Over the last decade or so, there has been a growing body of scientific and academic research indicating the potential of psychedelic compounds to address the limitations of current treatment opportunities for psychiatric and neurological conditions. These substances, such as psilocybin, 5-MeO-DMT and MDMA, have demonstrated impressive therapeutic effects in clinical trials, particularly in conditions like TRD, anxiety and post-traumatic stress disorders (PTSD). For example, a study by Johns Hopkins in 2021 found that treatment with psilocybin relieved symptoms of major depressive disorder, or depression, in adults with the condition for up to a month and a follow-up study of those participants in 2022 showed that the antidepressant effects of psilocybin-assisted therapy, when given with supportive psychological support, lasted at least a year for some patients.<span class="__superscript" style="color:rgb(38,37,35)">3 </span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Another study, run by Lykos Therapeutics (previously MAPS PBC), found that patients with PTSD showed significant improvement when receiving MDMA-assisted therapy compared with therapy and placebo.<span class="__superscript" style="color:rgb(38,37,35)">4 </span>Some pharma companies are assessing their own candidates for TRD, alcohol use disorder and major depressive disorder. While there still remains some debate as to exactly how psychedelics elicit their therapeutic effects, current research suggests that it is the induction of a neuroplastic state, as well as an altered state of consciousness, that enables medical benefit.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Neuroplasticity refers to the alteration of the structure and function of neurons, the nerve cells that transmit information within the brain, while altered states of consciousness refers to the psychological state induced by psychedelics that can elicit new perspectives or thoughts that are not usually accessible with everyday consciousness. It is the combination of these two states that can induce deep introspection and emotional processing, which, in turn, could potentially help shift ingrained patterns of thinking or behaviours.</p></div></div><div id="outer" data-widget="image-widget" style="background-color:transparent;padding:8px 24px 16px 24px;min-height:auto" class="Widget-module_outer__PBh8P"><div id="inner" class="Image-module_container__8raIv Image-module_container-noflex__-J1PG" style="border-radius:0px 0px 0px 0px;width:100%;min-height:auto"><picture class="Image-module_picture__gw1zY Image-module_loading__FfyPr"><source type="image/jpeg" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw"/><img src="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=768" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw" class="Image-module_image__w4slc" width="100%" height="475" decoding="async" alt="Image" style="height:auto;width:100%"/></picture></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">What other indications can psychedelic medicines be utilised in?</span><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)"> </span></span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">RC: </span>Psychedelic medicines are being investigated as potential treatments for a wide range of indications beyond depression, anxiety and PTSD. Several studies have indicated the utility of psychedelic treatments for substance abuse and alcohol abuse conditions, and there is emerging evidence that points to the potential of psychedelics <span>to help with eating disorders like anorexia nervosa and bulimia nervosa.</span><span class="__superscript">5,6 </span><span>Other studies have explored how psychedelics might assist in palliative care by helping to reduce end-of-life anxiety. A 2016 study found that a single, high-dose of psilocybin given to individuals with life-threatening cancer diagnoses led to a decrease in clinicianand self-rated measures of depression, anxiety and death anxiety, along with increases in quality of life, life meaning and optimism.</span><span class="__superscript">7 </span><span>It is a very exciting time for psychedelic and neuropsychiatric research, and we are only at the start of realising the full potential of these compounds.</span></p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">What are the barriers facing the development of more psychedelic medicines?</span><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)"> </span></span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">RC: </span>Despite the growing body of evidence supporting the potential of psychedelics to address some of the most intractable neuropsychiatric conditions in society, there are still a number of barriers to actually bringing these compounds to market.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>In most countries, psychedelics remain a controlled and scheduled substance, which makes researching them and conducting clinical trials on them more difficult. Stigma also plays a big role. Psychedelics carry a lot of historical baggage and, despite the hype around recent scientific breakthroughs, there continue to be many misconceptions and biases that can blunt public acceptance and scientific progress.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Hopefully following the science and building evidence of best practice and efficacy, those beliefs can change over time. Another challenge is that, because these compounds are relatively new in the medical sphere, there is a lack of standardised protocols for running clinical trials with psychedelics or for providing psychological support alongside their use, which is a barrier to appropriate regulatory oversight and market access. However, there are signs this is changing. In June 2023, the US Food and Drug Administration (FDA) published draft guidance for sponsors developing psychedelic drugs for the treatment of medical conditions, including considerations for designing clinical trials. This was an early signal that work is being done to think about how these novel treatments may eventually integrate into existing healthcare systems.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Overcoming these barriers will require collaborative efforts among researchers, policymakers, healthcare professionals and advocacy groups to ensure responsible and equitable access to psychedelic medicines.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h3><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)">Pharmafile: </span></span><span class="__bold" style="color:rgb(38,37,35)">How do you see the field of psychedelics developing in the next five years?</span><span class="__italic"><span class="__bold" style="color:rgb(38,37,35)"> </span></span></h3></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">RC: </span>There is a lot to be optimistic about. With more interest and investment in this space, we are likely to see more efforts to standardise best practice for psychedelic clinical research and developments, as well as efforts to reschedule psychedelic compounds and enable wider patient access to their therapeutic potential. The US is already making good progress on this front and we may even see MDMA-assisted therapy (MDMA-AT) for PTSD available to those in need within the year. Indeed, Lykos Therapeutics, who successfully completed a phase 3 study of MDMA-AT for PTSD last year, announced in February 2024 that the FDA had accepted their new drug application for MDMA-AT for PTSD and had granted the application priority review with a Prescription Drug User Fee Act target action date of 11 August 2024. If approved, this would be the first MDMA-assisted therapy available in the US.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>More broadly, there are other signs that the US medical landscape is preparing for a future where psychedelic medicines are available. The American Medical Association’s Current Procedural Terminology (CPT) III codes for psychedelic-assisted therapies officially went into effect on 1 January 2024. These codes give physicians and qualified healthcare providers a mechanism to seek reimbursement for administering psychedelic-assisted therapy if approved by the FDA. These developments show increasing recognition from medical authorities about the potential of psychedelic therapies and set the scene for how psychedelic medicine may be integrated into mainstream mental health care settings in the future. Challenges around ensuring equitable access, appropriate reimbursement and public education will likely still remain but, as above, with a coalition of voices from across the psychedelic medicine field, we could see a bright future for the treatment of psychiatric and neurological conditions.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:80%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__italic">References</span><br/><ol><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://nature.com/articles/s41380-021-01200-3">nature.com/articles/s41380-021-01200-3</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://pubmed.ncbi.nlm.nih.gov/11918502/">pubmed.ncbi.nlm.nih.gov/11918502/</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-majordepression-effective-for-up-to-a-yearfor-most-patients-study-shows">hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-majordepression-effective-for-up-to-a-yearfor-most-patients-study-shows</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://lykospbc.com/2023-01-05-MAPSPBC-Announces-Positive-Resultsfrom-Confirmatory-Phase-3-MAPP2Trial-of-MDMA-Assisted-Therapy-forTreatment-of-PTSD">lykospbc.com/2023-01-05-MAPSPBC-Announces-Positive-Resultsfrom-Confirmatory-Phase-3-MAPP2Trial-of-MDMA-Assisted-Therapy-forTreatment-of-PTSD</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://onlinelibrary.wiley.com/doi/full/10.1111/adb.13229#:~:text=After%20the%20psychedelic%20experience%2C%2083,met%20Alcohol%20Use%20Disorders%20criteria.&text=58%25%20of%20participants%20reduced%20or%20stopped%20their%20alcohol%20since%20commencing%20microdosing.">onlinelibrary.wiley.com/doi/full/10.1111/adb.13229#:~:text=After%20the%20psychedelic%20experience%2C%2083,met%20Alcohol%20Use%20Disorders%20criteria.&text=58%25%20of%20participants%20reduced%20or%20stopped%20their%20alcohol%20since%20commencing%20microdosing.</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://pubmed.ncbi.nlm.nih.gov/37352816/">pubmed.ncbi.nlm.nih.gov/37352816/</a></span></li><li><span class="__italic">Visit: <a class="__link" target="_self" href="https://pubmed.ncbi.nlm.nih.gov/27909165/">pubmed.ncbi.nlm.nih.gov/27909165/</a></span></li></ol></p></div></div><div id="outer" data-widget="container-widget" style="background-color:transparent;padding:0px 24px 0px 24px;min-height:auto" class="Widget-module_outer__PBh8P Container-module_outer__Ae8eB"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div><div id="outer" data-widget="columns-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P"><div id="inner" class="Columns-module_inner__KeVpm Columns-module_collapse-phone__abOHb" style="border-radius:0px 0px 0px 0px;width:100%"><div class="Columns-module_column__hw-5a" style="margin:0px 12px;flex:4"><div id="outer" data-widget="column-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P Column-module_outer__vEJ6X"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="image-widget" style="background-color:transparent;padding:8px 0px 16px 0px;min-height:auto" class="Widget-module_outer__PBh8P"><div id="inner" class="Image-module_container__8raIv Image-module_container-noflex__-J1PG" style="border-radius:0px 0px 0px 0px;width:100%;min-height:auto"><picture class="Image-module_picture__gw1zY Image-module_loading__FfyPr"><source type="image/jpeg" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw"/><img src="https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=768" srcSet="https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw" class="Image-module_image__w4slc" width="100%" height="826" decoding="async" alt="Image" style="height:auto;width:100%"/></picture></div></div></div></div></div><div class="Columns-module_column__hw-5a" style="margin:0px 12px;flex:8"><div id="outer" data-widget="column-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P Column-module_outer__vEJ6X"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:8px 0px 8px 0px;text-align:left;font-size:80%;line-height:1.5;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">Dr Rob Conley </span>is chief scientific and medical officer at <span class="__bold">Beckley Psytech</span>, in this role, he oversees all of Beckley Psytech’s preclinical and clinical research and development. Rob previously served as senior vice president at Eleusis and chief science officer, Neuroscience at Eli Lilly and Co. Prior to that, he had a long academic career, first at the University of Pittsburgh, US, and at the University of Maryland School of Medicine, US, where he remains an adjunct professor of Psychiatry and Psychopharmacology. He holds an MD from the University of Maryland School of Medicine and a BA from the Johns Hopkins University, both US, and he completed a Psychiatry residency at the University of Pittsburgh, US, where he served as the chief resident. Rob is also a fellow of the American College of Neuropsychopharmacology.</p></div></div></div></div></div></div></div><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div></div></div></div></div></div><div class="_slug__share-button__ettip"><hr/></div></div></div><div id="ControlBar" class="_slug__control-bar__Jj4LE"><div class="WrapAutoHide-module_navigation__9sdQy WrapAutoHide-module_visible__UN7GD"><div class="ControlBar-module_toc-wrapper__AF5eD"><div class="ControlBar-module_toc__mKXnp"><div class="ControlBar-module_white-blur__TGapK"><div class="ControlBar-module_toc-slider__i9fv1"></div></div><div class="ControlBar-module_control-bar__9Zqak"><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><path d="M13.8287 19C13.5367 19 13.2467 18.873 13.0487 18.627L8.22066 12.627C7.92266 12.256 7.92666 11.726 8.23166 11.36L13.2317 5.35998C13.5847 4.93598 14.2157 4.87898 14.6407 5.23198C15.0647 5.58498 15.1217 6.21598 14.7677 6.63998L10.2927 12.011L14.6077 17.373C14.9537 17.803 14.8857 18.433 14.4547 18.779C14.2707 18.928 14.0487 19 13.8287 19Z" fill="white"></path></svg></button><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="18" height="14" viewBox="0 0 18 14" fill="none"><path d="M6.75 0H1.125C0.503719 0 0 0.503719 0 1.125V4.5C0 5.12128 0.503719 5.625 1.125 5.625C1.74628 5.625 2.25 5.12128 2.25 4.5V2.25H6.75C7.37128 2.25 7.875 1.74628 7.875 1.125C7.875 0.503719 7.37128 0 6.75 0Z" fill="white"></path><path d="M16.875 0H11.25C10.6287 0 10.125 0.503719 10.125 1.125C10.125 1.74628 10.6287 2.25 11.25 2.25H15.75V4.5C15.75 5.12128 16.2537 5.625 16.875 5.625C17.4963 5.625 18 5.12128 18 4.5V1.125C18 0.503719 17.4963 0 16.875 0Z" fill="white"></path><path d="M16.875 7.875C16.2537 7.875 15.75 8.37872 15.75 9V11.25H11.25C10.6287 11.25 10.125 11.7537 10.125 12.375C10.125 12.9963 10.6287 13.5 11.25 13.5H16.875C17.4963 13.5 18 12.9963 18 12.375V9C18 8.37872 17.4963 7.875 16.875 7.875Z" fill="white"></path><path d="M6.75 11.25H2.25V9C2.25 8.37872 1.74628 7.875 1.125 7.875C0.503719 7.875 0 8.37872 0 9V12.375C0 12.9963 0.503719 13.5 1.125 13.5H6.75C7.37128 13.5 7.875 12.9963 7.875 12.375C7.875 11.7537 7.37128 11.25 6.75 11.25Z" fill="white"></path></svg></button><button class="" disabled=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><g opacity="0.25"><path d="M9.9995 19C9.7735 19 9.5465 18.924 9.3595 18.768C8.9355 18.415 8.8785 17.784 9.2315 17.36L13.7075 11.989L9.3925 6.62701C9.0465 6.19701 9.1145 5.56701 9.5445 5.22101C9.9755 4.87501 10.6045 4.94301 10.9515 5.37301L15.7795 11.373C16.0775 11.744 16.0735 12.274 15.7685 12.64L10.7685 18.64C10.5705 18.877 10.2865 19 9.9995 19Z" fill="white"></path></g></svg></button></div></div></div></div></div><div class="_slug__wrapper__0ZIJf"></div><div></div></div></div><script> //create a new element const terms = document.createElement('div'); //set id terms.setAttribute("id","billboard-banner"); //add the new element to html var body = document.querySelector('body'); body.appendChild(terms); document.querySelector("#billboard-banner").innerHTML = "<ins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'></ins>"; //insert new element before header //document.body.insertAdjacentElement('afterbegin', terms); const insElement = document.querySelector("#__next"); insElement.before(terms); </script> <script async="" src="//ads.datateam.co.uk/www/delivery/asyncjs.php"></script><div class="_footer_j8nu5_1"><div class="_container_j8nu5_12"><div class="_footer-row_j8nu5_23"><div class="_footer-column_j8nu5_36 _flex-2_j8nu5_117"><div class="_footer-brand_j8nu5_43"><div class=""><img alt="Logo" loading="lazy" width="40" height="40" decoding="async" data-nimg="1" class="_footer-logo_j8nu5_57" style="color:transparent" srcSet="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 1x, https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 2x" src="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png"/></div><div class="_content_j8nu5_67"><h3>Pharmafile</h3><p>Therapeutic areas in focus</p></div></div><div class="_footer-link-list_j8nu5_121"><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" rel="noreferrer" href="mailto:info@samedanltd.com"><div class="_form-email_1lm7t_143 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>info@samedanltd.com</span></a></div><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://pwa.magloft.com/"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>www.samedanltd.com</span></a></div><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Privacy Policy</span></a><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Terms of Service</span></a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_status-accent_1lm7t_91 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Categories</h3><p>Explore our inspiring content by topic</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" href="/categories/infectious-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Infectious Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/rare-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Rare Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/dermatology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Dermatology</a><a class="_footer-link-item_j8nu5_92" href="/categories/oncology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Oncology</a><a class="_footer-link-item_j8nu5_92" href="/categories/respiratory"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Respiratory</a><a class="_footer-link-item_j8nu5_92" href="/categories/pain"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Pain</a><a class="_footer-link-item_j8nu5_92" href="/categories/neurology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Neurology</a><a class="_footer-link-item_j8nu5_92" href="/categories/cardiovascular"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Cardiovascular</a><a class="_footer-link-item_j8nu5_92" href="/categories/womens-health"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Women's Health</a><a class="_footer-link-item_j8nu5_92" href="/categories/news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>News</a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_share-action_1lm7t_463 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Social Footprints</h3><p>Follow us on our Social Media Channels</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://twitter.com/pharmafocus"><div class="_share-twitter_1lm7t_487 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">X</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://www.linkedin.com/company/samedan-ltd/"><div class="_share-linkedin_1lm7t_483 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">linkedin</span></a></div></div></div></div></div></div><div class="Toastify"></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"domain":"magazine.pharmafile.com","pwa":{"id":663,"publicationId":14881,"pwaOptinId":655,"domain":"magazine.pharmafile.com","config":{"access":{"concurrentLimit":null,"restrictAnonymous":null,"disableSignup":null,"disableLogin":null,"disableLoginMessage":null,"disableSearchIndexing":false,"signupUrl":null,"resetPasswordUrl":null,"isUsernameLogin":null,"disableEditProfile":null,"formUrl":null,"customMarginResetPassword":null},"push":{"google":{"serverPublicKey":"BM0A-3PI9oRiVvVNuci8EbmGIC655KFzdqh9tQxnt5n6T-oECeS2hReTgrjYtIeeK0wsWfMB6VixaHT_RxZ15J0"}},"tracking":{"facebook":{"appId":null,"pixelId":null},"google":{"measurementId":"G-L1MVP1ECDJ"},"gtm":null,"sentry":true},"payment":{"stripe":null,"bypassPayment":null,"mode":"none","external":null,"currency":null},"email":{"readerOptin":false},"firebase":null,"customHtml":{"head":"\u003clink rel=\"stylesheet\" href=\"https://use.typekit.net/nat8xfl.css\"\u003e\n\u003cscript type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1\u0026always=1\u0026showNoConsent=1\" onload=\"setupCookieBar();\"\u003e\u003c/script\u003e\n\u003c!-- Google Search console Verification --\u003e\n\u003cmeta name=\"google-site-verification\" content=\"1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0\" /\u003e\n\u003cstyle\u003e\n#billboard-banner { text-align:center;}\n#billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;}\n\u003c/style\u003e","body":"\u003cscript\u003e\n //create a new element\n const terms = document.createElement('div');\n //set id\n terms.setAttribute(\"id\",\"billboard-banner\");\n //add the new element to html\n var body = document.querySelector('body');\n body.appendChild(terms);\n document.querySelector(\"#billboard-banner\").innerHTML = \"\u003cins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'\u003e\u003c/ins\u003e\"; \n //insert new element before header\n//document.body.insertAdjacentElement('afterbegin', terms);\n const insElement = document.querySelector(\"#__next\");\n insElement.before(terms);\n\u003c/script\u003e\n\u003cscript async src=\"//ads.datateam.co.uk/www/delivery/asyncjs.php\"\u003e\u003c/script\u003e"},"account":{"emailEditable":true,"customSubscriptionText":null,"customSubscriptionURL":null,"enableSubscriptionTitle":null},"checkout":null},"design":{"colors":{"backgroundColor":"#FFFFFF","primaryColor":"#1976D2","secondaryColor":"#795FF4","accentColor":"#D76FD6","infoColor":"#41638C","warningColor":"#EF9338","successColor":"#20AD27","dangerColor":"#DF4241","topMenuBackgroundColor":"#FFFFFF","topMenuHeadingTitleColor":"#000000","topMenuHeadingIconColor":null,"topMenuItemTextColor":"#000000","topMenuItemIconColor":"#000000","footerMenuBackgroundColor":"#000000","footerMenuHeadingTitleColor":null,"footerMenuHeadingTextColor":null,"footerMenuHeadingIconColor":null,"footerMenuItemTextColor":null,"footerMenuItemIconColor":null},"images":{"icon":"https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png","feature":"https://cdn.magloft.com/defaults/feature-graphic.jpg","topMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png","footerMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png","alphaChannelIcon":null},"fonts":{"heading":"roboto-slab","body":"open-sans","ui":"roboto","topMenuTitle":"roboto-slab","topMenuItems":null,"topMenuSubtitle":null,"footerMenuTitle":"roboto-slab","footerMenuItems":null},"menuItems":{"collections":{"title":"Issues"},"articles":{"title":null},"account":{"title":null},"icons":{"enabled":true}},"footerShape":"flat","issueCoverAspectRatio":0.75,"fullscreenCollectionView":"auto","customOverlayToggleView":false,"defaultViewMode":"html","categories":"flat","purchaseList":true,"libraryList":false,"noteList":false,"textToSpeech":false},"layout":{"banners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","title":"Pharmafile Magazine","isHidden":true,"action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"bottomBanners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","title":"Samedan","isHidden":false,"action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"columnSeparator":"shadow","tabs":[{"route":"","title":"Home","icon":"menu-home","visible":true},{"route":"/articles","title":"Articles","icon":"menu-articles","visible":true},{"route":"/collections","title":"Collections","icon":"menu-issues","visible":true},{"route":"/account","title":"Account","icon":"menu-account","visible":true}],"topMenu":{"showLogo":true,"showSubtitle":true,"showTitle":false,"height":"64px"},"navbar":{"animation":false,"style":"logo-left"},"sections":[{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","isHidden":true,"title":"Pharmafile Magazine","action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]},{"fullWidth":false,"backgroundColor":null,"columnSeparator":"shadow","columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","isHidden":false,"title":"Samedan","action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]}],"columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},"seo":{"home":{"title":"Pharmafile - Therapeutic Areas in focus","description":"Pharma and healthcare legal \u0026 regulatory requirements, financial trends, research, tech, innovation, market insights, analysis, case studies and more","image":"https://cdn.magloft.com/pwa-663/seo/image/9a7a0d77-c45b-4ca4-8317-060aec365417.png","imageAlt":"Pharmafile magazine covers"},"articles":{"title":"Pharmafile Articles","description":"In depth articles covering AI Drug Discovery, Biomarkers, Drug Development, Clinical Trials, Personalised Medicine, Gene Editing, Biosimilars, Market Access, Real World Data, Wearables/ Interventional Devices and Patient Experience","image":"https://cdn.magloft.com/pwa-663/seo/image/a32f5169-eb7c-4073-9c9c-517e7c19e85d.png","imageAlt":"Pharmafile - Articles"},"issues":{"title":"Editions of Pharmafile","description":"Pharmafile includes in depth analysis of therapy areas including: Oncology, Pain Management, Respiratory Diseases, Rare Diseases, Cardiovascular \u0026 Metabolic, Neurological Disorders","image":"https://cdn.magloft.com/pwa-663/seo/image/48839896-f6a6-4404-8744-5e2ef6e70111.png","imageAlt":"Pharmafile - Issues"},"account":{"title":"Pharmafile - Account","description":"Manage your Pharmafile Reader Account...","image":"https://cdn.magloft.com/pwa-663/seo/image/898ff4a9-6db8-47f0-b26b-e2774d221dc2.png","imageAlt":"Reader Account"}},"strings":{"app":{"title":"Pharmafile","subtitle":"Therapeutic areas in focus"},"social":{"facebook":null,"twitter":"https://twitter.com/pharmafocus","linkedin":"https://www.linkedin.com/company/samedan-ltd/","youtube":null,"instagram":null},"topMenu":{"title":null,"subtitle":"Therapeutic areas in focus"},"footerMenu":{"title":"Pharmafile","subtitle":null,"description":null,"email":["info@samedanltd.com"],"privacyUrl":"http://www.samedanltd.com/page/13","termsUrl":"http://www.samedanltd.com/page/13","links":[{"name":"www.samedanltd.com","url":"https://pwa.magloft.com/"}]},"pages":null},"customFonts":[],"phrases":{},"trialEndAt":null,"bypassSubscription":false},"publication":{"id":14881,"title":"Pharmafile","properties":{"subtitle":null,"appIcon":"images/defaults/app-icon.png","promotionalText":null,"companyName":null,"emailReplyTo":"","privacyUrl":null,"termsUrl":null}},"categories":[{"id":42210,"slug":"infectious-diseases","title":"Infectious Diseases","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42211,"slug":"rare-diseases","title":"Rare Diseases","color":"#444444","issueCount":0,"articleCount":16,"categoryGroupIds":[]},{"id":42212,"slug":"dermatology","title":"Dermatology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42331,"slug":"oncology","title":"Oncology","color":"#444444","issueCount":0,"articleCount":11,"categoryGroupIds":[]},{"id":42332,"slug":"respiratory","title":"Respiratory","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42333,"slug":"pain","title":"Pain","color":"#444444","issueCount":0,"articleCount":3,"categoryGroupIds":[]},{"id":42334,"slug":"neurology","title":"Neurology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42335,"slug":"cardiovascular","title":"Cardiovascular","color":"#444444","issueCount":0,"articleCount":5,"categoryGroupIds":[]},{"id":48101,"slug":"womens-health","title":"Women's Health","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42404,"slug":"news","title":"News","color":"#444444","issueCount":0,"articleCount":31,"categoryGroupIds":[]}],"pwaSubscriptions":[],"categoryGroups":[],"slug":"psychedelic-medicines-and-the-treatment-of-neurological-conditio","article":{"id":258238,"slug":"psychedelic-medicines-and-the-treatment-of-neurological-conditio","issueId":51652,"categoryIds":[42334],"title":"Psychedelic medicines and the treatment of neurological conditions","description":"Rob Conley from Beckley Psytech tells Pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future","image":"https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg","cover":"https://cdn.magloft.com/publication-14881/screenshots/articles/258238.jpg?ts=1716380467","date":1716332400000,"unlockType":"free","categories":[],"pdfPageId":"SGvYGfgYcAHH","visible":true,"showOnToc":true,"bookmark":false,"position":21,"publicationId":14881,"pwaOptinId":null,"seoDescription":"Rob conley from beckley psytech tells pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and ho","classificationIds":[],"pwaSubscriptionIds":[],"source":"typeloft2","trending":false,"html":"\u003cpage-widget padding=\"16 0 24 0\"\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003ePSYCHOACTIVES\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h2\"\u003e\u003cspan style=\"font-family: \u0026quot;Roboto Slab\u0026quot;;\" class=\"__bold\"\u003ePsychedelic medicines and the treatment of neurological conditions\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"8 24 8 24\" background-color=\"rgba(240,9,121,1)\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(0,0,0)\"\u003e\u003cspan style=\"color: rgb(255, 254, 254);\"\u003eRob Conley from Beckley Psytech tells \u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(255, 254, 254);\"\u003ePharmafile \u003c/span\u003e\u003cspan style=\"color: rgb(255, 254, 254);\"\u003eabout the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future\u003c/span\u003e\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"8 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eWhat is the current treatment landscape for psychiatric and neurological conditions?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRob Conley (RC): \u003c/span\u003ePsychiatric conditions like depression and anxiety are primarily managed today through a combination of lifestyle changes, talking therapies and medications, with selective serotonin reuptake inhibitors (SSRIs) being the most common drugs prescribed by doctors or physicians for depression. Neurological conditions often have a different set of interventions available, combining a mix of physical therapy, medications and cognitive rehabilitation exercises. For many people living with neuropsychiatric conditions, the currently available treatments work for them but for others, there can be limited efficacy and challenges that limit treatment adherence, including undesirable side effects and a slow onset of action. Despite many years of work and experience in this field, there remains a strong need for new approaches in order to improve patient outcomes and reduce the burden these conditions have on individuals, healthcare systems and society more generally.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eWhat are the issues with current treatments for these conditions?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRC: \u003c/span\u003eThere are several challenges with the current treatment paradigm for neuropsychiatric conditions, and it may be helpful to look at depression, which typifies a lot of the hurdles we see within the space. For many patients, overcoming the stigma of accessing treatment or therapy \u003cspan\u003eis a big challenge, but once they get over that, there are still several difficulties they may encounter with the drug treatments themselves. Antidepressants and SSRIs may carry unwanted side effects like weight gain, sedation and sexual dysfunction that can lead to poor adherence and treatment discontinuation, while the slow onset of action of some medications can delay symptomatic relief and prolong a patients’ suffering. Antidepressants also have limited efficacy, with many people experiencing treatment resistance. Indeed, 33% of patients diagnosed with depression are resistant to available treatments and 60% of patients with depression discontinue or switch SSRI within 12 weeks.\u003c/span\u003e\u003cspan class=\"__superscript\"\u003e1,2 \u003c/span\u003e\u003cspan\u003eFor those living with treatment resistant depression (TRD), which is characterised when an individual with depression does not respond to two or more courses of antidepressants, treatment opportunities are sadly lacking and there is an urgent need for more effective treatments. Similar challenges can be seen across the treatment landscape for other psychiatric and neurological conditions.\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eHow can psychedelic medicines improve treatment of these illnesses?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRC: \u003c/span\u003eOver the last decade or so, there has been a growing body of scientific and academic research indicating the potential of psychedelic compounds to address the limitations of current treatment opportunities for psychiatric and neurological conditions. These substances, such as psilocybin, 5-MeO-DMT and MDMA, have demonstrated impressive therapeutic effects in clinical trials, particularly in conditions like TRD, anxiety and post-traumatic stress disorders (PTSD). For example, a study by Johns Hopkins in 2021 found that treatment with psilocybin relieved symptoms of major depressive disorder, or depression, in adults with the condition for up to a month and a follow-up study of those participants in 2022 showed that the antidepressant effects of psilocybin-assisted therapy, when given with supportive psychological support, lasted at least a year for some patients.\u003cspan class=\"__superscript\" style=\"color: rgb(38,37,35)\"\u003e3 \u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eAnother study, run by Lykos Therapeutics (previously MAPS PBC), found that patients with PTSD showed significant improvement when receiving MDMA-assisted therapy compared with therapy and placebo.\u003cspan class=\"__superscript\" style=\"color: rgb(38,37,35)\"\u003e4 \u003c/span\u003eSome pharma companies are assessing their own candidates for TRD, alcohol use disorder and major depressive disorder. While there still remains some debate as to exactly how psychedelics elicit their therapeutic effects, current research suggests that it is the induction of a neuroplastic state, as well as an altered state of consciousness, that enables medical benefit.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eNeuroplasticity refers to the alteration of the structure and function of neurons, the nerve cells that transmit information within the brain, while altered states of consciousness refers to the psychological state induced by psychedelics that can elicit new perspectives or thoughts that are not usually accessible with everyday consciousness. It is the combination of these two states that can induce deep introspection and emotional processing, which, in turn, could potentially help shift ingrained patterns of thinking or behaviours.\u003c/paragraph-widget\u003e\u003cimage-widget padding=\"8 24 16 24\" aspect-ratio=\"0.619\" magnify-label=\"center\" source=\"https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg#image/jpeg\"\u003e\u003c/image-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eWhat other indications can psychedelic medicines be utilised in?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRC: \u003c/span\u003ePsychedelic medicines are being investigated as potential treatments for a wide range of indications beyond depression, anxiety and PTSD. Several studies have indicated the utility of psychedelic treatments for substance abuse and alcohol abuse conditions, and there is emerging evidence that points to the potential of psychedelics \u003cspan\u003eto help with eating disorders like anorexia nervosa and bulimia nervosa.\u003c/span\u003e\u003cspan class=\"__superscript\"\u003e5,6 \u003c/span\u003e\u003cspan\u003eOther studies have explored how psychedelics might assist in palliative care by helping to reduce end-of-life anxiety. A 2016 study found that a single, high-dose of psilocybin given to individuals with life-threatening cancer diagnoses led to a decrease in clinicianand self-rated measures of depression, anxiety and death anxiety, along with increases in quality of life, life meaning and optimism.\u003c/span\u003e\u003cspan class=\"__superscript\"\u003e7 \u003c/span\u003e\u003cspan\u003eIt is a very exciting time for psychedelic and neuropsychiatric research, and we are only at the start of realising the full potential of these compounds.\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eWhat are the barriers facing the development of more psychedelic medicines?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRC: \u003c/span\u003eDespite the growing body of evidence supporting the potential of psychedelics to address some of the most intractable neuropsychiatric conditions in society, there are still a number of barriers to actually bringing these compounds to market.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eIn most countries, psychedelics remain a controlled and scheduled substance, which makes researching them and conducting clinical trials on them more difficult. Stigma also plays a big role. Psychedelics carry a lot of historical baggage and, despite the hype around recent scientific breakthroughs, there continue to be many misconceptions and biases that can blunt public acceptance and scientific progress.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eHopefully following the science and building evidence of best practice and efficacy, those beliefs can change over time. Another challenge is that, because these compounds are relatively new in the medical sphere, there is a lack of standardised protocols for running clinical trials with psychedelics or for providing psychological support alongside their use, which is a barrier to appropriate regulatory oversight and market access. However, there are signs this is changing. In June 2023, the US Food and Drug Administration (FDA) published draft guidance for sponsors developing psychedelic drugs for the treatment of medical conditions, including considerations for designing clinical trials. This was an early signal that work is being done to think about how these novel treatments may eventually integrate into existing healthcare systems.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eOvercoming these barriers will require collaborative efforts among researchers, policymakers, healthcare professionals and advocacy groups to ensure responsible and equitable access to psychedelic medicines.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h3\"\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eHow do you see the field of psychedelics developing in the next five years?\u003c/span\u003e\u003cspan class=\"__italic\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eRC: \u003c/span\u003eThere is a lot to be optimistic about. With more interest and investment in this space, we are likely to see more efforts to standardise best practice for psychedelic clinical research and developments, as well as efforts to reschedule psychedelic compounds and enable wider patient access to their therapeutic potential. The US is already making good progress on this front and we may even see MDMA-assisted therapy (MDMA-AT) for PTSD available to those in need within the year. Indeed, Lykos Therapeutics, who successfully completed a phase 3 study of MDMA-AT for PTSD last year, announced in February 2024 that the FDA had accepted their new drug application for MDMA-AT for PTSD and had granted the application priority review with a Prescription Drug User Fee Act target action date of 11 August 2024. If approved, this would be the first MDMA-assisted therapy available in the US.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 16 24\"\u003eMore broadly, there are other signs that the US medical landscape is preparing for a future where psychedelic medicines are available. The American Medical Association’s Current Procedural Terminology (CPT) III codes for psychedelic-assisted therapies officially went into effect on 1 January 2024. These codes give physicians and qualified healthcare providers a mechanism to seek reimbursement for administering psychedelic-assisted therapy if approved by the FDA. These developments show increasing recognition from medical authorities about the potential of psychedelic therapies and set the scene for how psychedelic medicine may be integrated into mainstream mental health care settings in the future. Challenges around ensuring equitable access, appropriate reimbursement and public education will likely still remain but, as above, with a coalition of voices from across the psychedelic medicine field, we could see a bright future for the treatment of psychiatric and neurological conditions.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 16 24\" font-size=\"80\"\u003e\u003cspan class=\"__italic\"\u003eReferences\u003c/span\u003e\u003cbr\u003e\u003col\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://nature.com/articles/s41380-021-01200-3\"\u003enature.com/articles/s41380-021-01200-3\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://pubmed.ncbi.nlm.nih.gov/11918502/\"\u003epubmed.ncbi.nlm.nih.gov/11918502/\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://hopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-majordepression-effective-for-up-to-a-yearfor-most-patients-study-shows\"\u003ehopkinsmedicine.org/news/newsroom/news-releases/2022/02/psilocybin-treatment-for-majordepression-effective-for-up-to-a-yearfor-most-patients-study-shows\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://lykospbc.com/2023-01-05-MAPSPBC-Announces-Positive-Resultsfrom-Confirmatory-Phase-3-MAPP2Trial-of-MDMA-Assisted-Therapy-forTreatment-of-PTSD\"\u003elykospbc.com/2023-01-05-MAPSPBC-Announces-Positive-Resultsfrom-Confirmatory-Phase-3-MAPP2Trial-of-MDMA-Assisted-Therapy-forTreatment-of-PTSD\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://onlinelibrary.wiley.com/doi/full/10.1111/adb.13229#:~:text=After%20the%20psychedelic%20experience%2C%2083,met%20Alcohol%20Use%20Disorders%20criteria.\u0026amp;text=58%25%20of%20participants%20reduced%20or%20stopped%20their%20alcohol%20since%20commencing%20microdosing.\"\u003eonlinelibrary.wiley.com/doi/full/10.1111/adb.13229#:~:text=After%20the%20psychedelic%20experience%2C%2083,met%20Alcohol%20Use%20Disorders%20criteria.\u0026amp;text=58%25%20of%20participants%20reduced%20or%20stopped%20their%20alcohol%20since%20commencing%20microdosing.\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://pubmed.ncbi.nlm.nih.gov/37352816/\"\u003epubmed.ncbi.nlm.nih.gov/37352816/\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan class=\"__italic\"\u003eVisit: \u003ca class=\"__link\" target=\"_self\" href=\"https://pubmed.ncbi.nlm.nih.gov/27909165/\"\u003epubmed.ncbi.nlm.nih.gov/27909165/\u003c/a\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e\u003c/paragraph-widget\u003e\u003ccontainer-widget padding=\"0 24 0 24\"\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003ccolumns-widget collapse=\"phone\" gutter=\"24\" layout=\"4 8\"\u003e\u003ccolumn-widget\u003e\u003cimage-widget padding=\"8 0 16 0\" aspect-ratio=\"1.0755555555555556\" magnify-label=\"center\" source=\"https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg#image/jpeg\"\u003e\u003c/image-widget\u003e\u003c/column-widget\u003e\u003ccolumn-widget\u003e\u003cparagraph-widget padding=\"8 0 8 0\" line-height=\"1.5\" font-size=\"80\"\u003e\u003cspan class=\"__bold\"\u003eDr Rob Conley \u003c/span\u003eis chief scientific and medical officer at \u003cspan class=\"__bold\"\u003eBeckley Psytech\u003c/span\u003e, in this role, he oversees all of Beckley Psytech’s preclinical and clinical research and development. Rob previously served as senior vice president at Eleusis and chief science officer, Neuroscience at Eli Lilly and Co. Prior to that, he had a long academic career, first at the University of Pittsburgh, US, and at the University of Maryland School of Medicine, US, where he remains an adjunct professor of Psychiatry and Psychopharmacology. He holds an MD from the University of Maryland School of Medicine and a BA from the Johns Hopkins University, both US, and he completed a Psychiatry residency at the University of Pittsburgh, US, where he served as the chief resident. Rob is also a fellow of the American College of Neuropsychopharmacology.\u003c/paragraph-widget\u003e\u003c/column-widget\u003e\u003c/columns-widget\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003c/container-widget\u003e\u003c/page-widget\u003e","keywordPhrase":"psychedelic medicines and the treatment of","articleAssets":[{"url":"https://cdn.magloft.com/reader/fonts/roboto-slab.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/reader/fonts/open-sans.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/pdf-import/1066/images/img_26-1.jpg","extension":"jpeg","contentType":"image/jpeg"},{"url":"https://cdn.magloft.com/pdf-import/1066/images/img_28-1.jpg","extension":"jpeg","contentType":"image/jpeg"}]},"publicationId":14881},"__N_SSG":true},"page":"/domains/[domain]/articles/[slug]","query":{"domain":"magazine.pharmafile.com","slug":"psychedelic-medicines-and-the-treatment-of-neurological-conditio"},"buildId":"1bBCYhXOG7wsYuaBifvjK","isFallback":false,"gsp":true,"scriptLoader":[]}</script></body></html>